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Atral is a Portuguese Pharmaceutical firm devoted to the production of finished drugs. Due to 
domestic market hurdles, Atral is now, more than ever, focused in the world. The Central America 
region seams alluring due to its context alignment with firm’s resources bundle. As Atral should 
approach one regional country at a time, the purpose of this thesis is to find out the most suitable 
country to approach now. Hence a tailored scoring model was applied, based on contexts analysis 
and importance of benchmarking indicators to both firm and industry. Upon analysis of the highest 
scored country, the most appropriate entry modes were assessed. 
Key-words: Central America; Internationalization; Pharmaceutical Industry; Panama 
Introduction  
Laboratórios Atral (Atral) is a company member of an integrated chemical-pharmaceutical 
Portuguese Group, named AtralCipan (Appendix I (a)). Atralcipan, with a consolidated turnover of 
€37.3 mn in 20141, comprises three firms: Cipan2 (39.8% of consolidated turnover), Atral (54.7% 
of consolidated turnover) and Pharbal (5.5% of consolidated turnover). The Group is devoted to the 
production and commercialization of raw materials (Cipan) and finalized drugs (Atral and 
Pharbal3).  
Atral is an internationalized firm from inception. Due to domestic market hurdles (saturation, high 
competition, fragmentation) and a generalized expansive attitude of firms towards a single, 
borderless global marketplace, the firm is more than ever focused in consolidating its international 
position. Although abandoned in 2005, due to domestic penetration by generics4, Central America 
(CA), has once again been identified by Atral as a region with significant potential. Mainly due to 
generics poor penetration, as competitors are focused in pharmerging countries5, there is an 
opportunity in this familiar market. In this sense, the work project starts its analysis by a state of the 
                                                            
1 All non-mentioned dates throughout this work correspond to 2014 unless otherwise mentioned. 
2 Atral holds 51.1% of Cipan’s capital share. 
3 Pharbal is a sales subsidiary in Peru. 
4 Generics (unbranded or branded generics) are drugs generally intended to be interchangeable with an innovator drug. They are produced 
without a license from the innovator firm and marketed after the expiry date of the patent or other exclusive rights (Gupta and Nayak 2015). 
5 Pharmerging countries are developing geographies where consumption of pharmaceuticals is rapidly growing. 
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art of SMEs internationalization theories, and identification of Atral’s internationalization strategy. 
It is followed by an appraisal of firm’s internal capabilities and global external context. Then a 
tailored scoring model is applied to the seven CA nations - Panama, Costa Rica, Nicaragua, 
Honduras, El Salvador, Belize and Guatemala. The highest scored country was then thoroughly 
analysed. In the end, appropriate entry modes are assessed and suggestions for the success of this 
internationalization strategy are presented. 
Methodology  
The methodology employed in the present strategic internationalization plan aims at a wide and 
comprehensive analysis of the external and internal contexts of the firm, and targeted foreign 
markets. A hybrid data collection approach was employed: first hand interviews to firm 
representatives, together with a thorough bibliographic research were executed. In order to fully 
understand firm’s internal dynamics, essential data was collected interviewing the heads of all firm 
departments, including one member of the Administration Board. In contrast, for cross-country data 
collection, data was gathered from worldwide data banks, countries’ statistical websites and 
publications held by consultancy companies and official institutions. Moreover, not only sector-
specific and general business articles and websites, but also strategy and international business 
books were consulted. 
Literature Review - Theories on Internationalization of SMEs 
Internationalization is “the process of adapting firms operations (strategy, structure, resources, 
etc.) to international environments” (J. Johanson and Mattsson 1993). Mainly over the past twenty 
years, an intensive growth on the research regarding companies’ internationalization, particularly 
the one directed by SMEs, has been a reality (Saeedi, Dadfar, and Brege 2012; Sandberg 2012). 
This later type of internationalization can be analysed through four main perspectives: (1) Stage; 
(2) Network; (3) International Entrepreneurship (IE); and (4) resource-based (RBV) perspectives. 
RBV in contrast to the first two approaches does not neglect the strategic view of decision-makers 
(Ruzzier, Hisrich, and Antoncic 2006). Regarding the Stage/Behavioral approach to the 
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internationalization process, there are essentially two main models: the Uppsala Internationalization 
Model (U-model); and the Innovation-related Model (I-model). The U-model (Johanson & Vahlne 
(1977, 1990) is built upon the behavioral theory of the firm  (Cyert and March 1963) and the theory 
of knowledge and change in firms (Penrose 1959). It depicts the internationalization process as one 
characterized by progressive learning (Jan Johanson and Vahlne 1977) in a synergic cycle between 
market knowledge, commitment decisions, current activities and market commitment (dynamic 
model) (Jan Johanson and Vahlne 2009). The gradually procured, and then integrated, knowledge 
in external markets is applied as input for the decision-making process, making internationalization 
the outcome of many cumulative decisions, that in turn reflect resources commitment (Ruzzier, 
Hisrich, and Antoncic 2006; J. Johanson and Vahlne 1990). Psychic Distance6 also determines 
internationalization: firms elect external markets culturally closer to domestic market (Jan Johanson 
and Vahlne 2009). On the other hand the I-Model (Bilkey and Tesar 1977; Cavusgil 1980; Reid 
1981; Czinkota 1982) acknowledges every step of the process as an innovation for the 
internationalizing entity (Li, Li, and Dalgic 2004). The model focus entirely on the export 
development process, particularly for SMEs, being characterized by three generic stages: Pre-
engagement, Initial and Advanced export (Ruzzier, Hisrich, and Antoncic 2006). Despite 
considering a progressive involvement of the firm the I-Model explains internationalization as an 
even more incremental process,  involving an innovative decision process in which new approaches 
of doing business are embraced; it is determined by countless firm-specific and managerial factors, 
and depends on internationalization degree of firms (Oliveira 2011). These stage approaches 
although considerably enlightening, they do not explain the rapid international development of 
some SMEs, allowing the rise of other approaches like Network and IE perspectives. The 
Network/Relational perspective, was built upon the U-Model (J. Johanson et al. 1988). The model 
depicts the market as a web of networks and considers the firm as an actor in a multinational 
                                                            
6 Psychic Distance was defined “as the sum of factors preventing the flow of information from and to the market. Examples are differences in 




structure of intra and inter-organizational long-term relationships (multilateral network). Relations 
are seen as trust and commitment-building, knowledge creation and accumulation systems. A 
company relies upon the resources controlled by the players embedded in a particular network, 
being only able to access it (intangible asset) by expanding its position in the network to a relevant 
one, implying time and resources commitment – liability of outsidership (Jan Johanson and Vahlne 
2009). Internationalization is pictured to develop once the company starts establishing bonds with 
firms from business networks in foreign countries, which eventually will act as a catwalk to new 
markets (M. Johanson and Kao T. 2010). The IE perspective is the confluence between 
entrepreneurship and international business research streams (McDougall, P.P. and Oviatt 2000). 
This model emerged due to identification of small, high-tech companies which internationalization 
steps diverted from the traditionally proposed: the Born Globals. These firm types start 
internationalizing from the beginning, surpassing 25% of export share in the first three years of 
existence; and they generally do not follow an incremental internationalization (Sandberg 2012). 
Internationalization depends deeply on entrepreneur’s attributes, experience and network of 
relations; he is a proactive actor, regarded as the fundamental engine of a company’s value creation 
and internationalization. However, IE is considered too holistic; not giving enough attention to the 
structure and interactions within networks, and overlooking mature SMEs as potential innovators 
(Slotte-Kock and Coviello 2010). Finally, RBV has been growingly employed to explain 
internationalization of SMEs (Sandberg 2012; Saeedi, Dadfar, and Brege 2012; Ruzzier, Hisrich, 
and Antoncic 2006). It is emerging based on existing models, as an holistic but precise dynamic 
capabilities/resources-based theory of the firm (Ruzzier, Hisrich, and Antoncic 2006). RBV was 
built upon business strategy and the theory of growth of the firm (Penrose 1959). This model 
perceives not only the significant role of singular costly-to-copy knowledge-based resources in 
granting a sustainable competitive advantage, but aim on the dynamic competence of organizational 
learning needed for new resources development, and adjustment (within the firm, and between firm 
and surroundings) in response to internal/external stimulations (Ahokangas 1998). Firms may seek 
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distinct internationalization strategies, with distinct international activities across time (Ruzzier, 
Hisrich, and Antoncic 2006). However RBV is regarded by some scholars as static, not enough to 
explain internationalization processes. Indeed, one should be aware that this economic perspective, 
once originally developed in leading economy contexts, like stage and network perspectives, 
sometimes alone do not precisely apply to SMEs internationalisation process (Sandberg 2012).  
Having in mind the turn of internationalization events regarding Atral, there is no single model that 
suits the pattern at hands. Due to the internationalization from inception, with firm’s rapid growth 
driven by founder’s visionary and entrepreneurial skills, allied with the solid and wide network in 
which Atral is inserted (which has strongly determined expansion abroad), the Network Approach 
together with IE seem to be the most suitable models to explain the initial developments of Atral’s 
internationalization. The model of resource adjustment is thought to explain firm’s mature stage 
and present internationalization – adaptation to generics market invasion by developing or 
improving new competences, such as significant focus in contract manufacturing (flexibility) and 
enhancing its global network. 
Company Overview   
National and International Involvement 
Atral began operations in 1947. Exportations began in 1949, first to Africa and Middle East, and 
then North and South Americas.  
Nowadays, with 212 employees, the firm devotes itself to the production of branded generics7 and, 
as a domestic precursor in antibiotics, it keeps on this important therapeutic area, the main axis of 
its development. All firm patents have expired and no research on innovative products is done. 
However, Atral constantly monitors the market to identify diversified products whose patent is 
going to expire, not only to recreate it, but also redevelop its production to minimize costs, and/or 
develop new dosage and administration forms to introduce in the market. Licensing out (2.5% of 
the €21.9 mn turnover expected for 2015) as well as contract development and manufacturing 
                                                            
7 Branded generics are: 1) novel dosage or potency forms of off-patent medicines that were not developed by the firm marketing the original 
drug; or 2) a generic drug (knockoff of a branded drug after all patents on the drug had expired) to which was given a trade name. 
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services (6.0% of 2015 turnover) comprise the other areas of activity. The firm continues to be 
inserted in countless markets over the globe, commercializing and exporting products for more than 
20 countries worldwide: mainly to Venezuela (52.2%8), Peru (17.9%7), Iraq (4.8%7), Dominican 
Republic (4.4%7), Angola (4.2%7), Libya (3.6%7), Lebanon (3.2%7), and Israel (3.2%7) (Appendix 
I (b)). Exports contributed 39% to 2015 turnover, from which 80% are Atral’s own brand anti-
infectives9, and 7.0% correspond to contract manufacturing. The firm has seen its turnover slightly 
decrease over the last 4 years in contrast to a growth in export sales (Appendix 1 (b)).  
In Portugal, Atral’s main market (61% of 2015 turnover), the firm holds an exemplar reputation 
being one of the most recognized national born brands (a stable market share in value of 0.78% 
(0.86% in units) against 4.19% of  Bial, or 5.81% of the largest player, MSD). It relies in a 30 people 
commercial team that works near physicians, pharmacies and hospitals. Indeed the economies of 
learning generated by Atral over time, allows it to supply quality products at competitive prices 
(cost-effectiveness strategy). As part of an integrated Pharmaceutical Group performing both 
upstream and downstream activities on the pharmaceutical value chain (including 
commercialization) addressing the whole industry, Atral is endowed with a levered global market 
knowledge and network, thanks to generated synergies.  
Atral’s domestic business model builds upon working its own brand; internationally it builds upon 
the in-licensing of products (36% of sales) and own brand working (64% of sales). The firm directs 
itself to the association of a powerful presence in regulated niche markets (non-strategic for big 
innovative and generic multinationals, and endowed usually with higher growths), with a high cost-
effective commercial portfolio. 
Vision, Mission and Values 
Without a consolidated vision, Atral’s main mission is “to develop, produce and commercialize 
finished, health and well-being products that contribute to life quality improvement”, complying 
                                                            
8 Average sales value from Dec. 2011 until September 2015. 
9 Pharmaceuticals that can destroy an infectious agent or inhibit it from spreading. They comprise antibiotics and antibacterials, antifungals, 
antivirals and antiprotozoals. 
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with its values: Commitment to its human capital, shareholders, customers and community in which 
it operates; Compliance with legislations; Respect for the final costumer, their health and well-being 
(Humanism); Persistence in finding sustainable health solutions; Environment Conscience; 
Integrity; Resilience and Stability. 
Strategic Objectives 
The firm expects to considerably increase by 15% its 2015 expected turnover of €21.9 mn already 
in 2016, by 1) domestically launching three new products and re-launching others; and 2) by 
internationally registering, launching and re-launching 20 products in Latin America (LA), Middle 
East and Africa (aggregated potential of €17.2 mn), until 2018. Moreover Atral wants to increase 
contract manufacturing weight on turnover.  
The firm also acknowledges the need to establish positions in strategic markets and its presence in 
emerging ones, thus: 1) it targets a growth of 61.1% on its own brand exports, from a value of €5.3 
mn to a value of €8.5 mn in 2017; 2) the reduction of its dependence on Venezuelan public market; 
3) diversification of target countries (penetration of Asian countries: Macau and Taiwan); 4) attain 
a domestically equivalent market share in CA region (0.78%) until 2017. Since financial stability 
is a key factor for Atral’s continued expansion, finding new investors or strategic partners is of 
utmost priority.  
Target Market and Portfolio  
Atral’s direct customers comprise pharmacies and parapharmacies (ambulatory market) and 
hospitals (hospital market), and also government (reimbursements and social coverage) and private 
insurance firms (private coverage). However it also has the indirect customers, from whom it cannot 
forget: physicians, and patients who need medicines inserted in Table 1 therapeutic classes (market 
segments). In a portfolio with 60 different main products, 22 are anti-infectives and belong to 
classes 3), 4) and 7). Regarding services, Atral mainly provides contract development and 
manufacturing services that comprises planning, production, packaging and logistics of finalized 
drugs for other firms (6.0% of turnover 2015, and 7.0% of exports). 
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Present in so many and so diverse markets, Atral faces several competitors in the branded-generics 
market (direct competition) nationally and worldwide, depending on the therapeutic class 
concerned. However non-branded generics are a considerably dangerous indirect competitor 
(margins). Appendix I (b) Table 1 shows firm domestic competitors per relevant therapeutic class. 
Competitive Advantage 
In an increasingly globalized economic structure Atral stands out from its competition mainly 
through the combination of: (1) its historic/reliable “Made in Portugal” label that grants it with 
domestic and international reputation, levered by Atral’s brand association with antibiotics and 
integration in a chemical-pharmaceutical Group; (2) its global market experiential knowledge and 
awareness together with its (3) unique and growing network of strategic alliances and (4) local 
governments relationships, granting Atral a surprising capability to penetrate poorly accessible 
markets; (5) learning economies, granting its ability to rapidly introduce products in the market 
(early and constant thorough market search on the potentially most profitable drugs to re/introduce 
in the market, generally with some added value (e.g. easier administration process,  healthy booster 
additives). Due to the intangibility character of Atral main resources, it can be assumed that they 
hold value, scarcity, are hard to imitate and transfer. However, the increasing market atomization, 
evolution of physicians and growing intervening role of patients promotes an easier substitutability 
of pharmaceutical products. Moreover the low professionalization of Atral undermines the firm 
embeddedness of some resources, confining its exploitation. Thus one can argue that Atral has a 
temporary, not a sustainable competitive advantage (Appendix I (b) Table 5). 
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Overall Analysis  
Atral has established over the years a broad customer base being able to generate still today a strong 
brand awareness, granting its present reputation in domestic and international markets. However, 
combined with Europe’s Economic crisis and austerity of last years, the lack of alignment between 
firm elements has been responsible for the slight decrease in firm’s income, and growth. Thus, the 
high potential organizational resources platform should be leveraged to capitalize on a much higher 
profitability for the firm. Indeed the domestic market is saturated and the continuous quest to enter 
new and niche-specific markets is alluring to boost sales, to reduce its reliance on domestic sales, 
and maybe attain scale economies. 
Context Overview 
The Pharmaceutical Industry 
The World Global Pharmaceutical Industry10 (Pharma) is characterized by high profit margins (up 
to 42% for innovative drugs11 (Anderson 2014)) and profitability exceeding costs. The industry is 
worth $990 bn (5% CAGR) (CPhI 2014) and it is estimated to range about $1.3 tn by 2018 (4-7% 
CAGR). This raise is explained by overlap between population increase and aging, enhanced 
accessibility to medicines in pharmerging markets, and launch of new specialty drugs. Regarding 
global generics market – where competition is mainly based on production costs (price), economies 
of scale and ability to litigate intricate patent issues – it was worth $168 bn in 2013, and it is 
estimated to value $283 bn by 2018 (at a 11% CAGR, despite its global price increase (Forbes 2015; 
Deloitte 2014)). This market will continue to be the main driver of Pharma global growth, primarily 
in pharmerging countries12 (83% of growth accounted by non-brand generics) (IMS 2014a).  
                                                            
10 World Global Pharmaceutical Industry comprises the generic and innovative medicines (on patent drugs) markets. 
11 Generic drugs (more precisely branded generics) are the ones with the highest profit margins compared to innovator drugs. Yet, total profits 
on the later are higher than the former, as firms retain exclusivity for a certain time span upon medicine approval. 
12 The first tier is composed by China (with a forecasted market size of $170-185 bn and accounting for 15% of global market in 2017; CAGR 
of 16.7% forecast in 2012-2017); the second tier is composed by Brasil (CAGR of 12.7% in 2012-2017), India (CAGR of 12.5% in 2012-
2017), Russia (10.1% CAGR in 2012-2017), all together with a forecasted market size of $91-99 bn and accounting for 8% of global market 
in 2017. The third tier of pharmerging countries comprise: countries with 2012 sales over $85/capita: Poland, Argentina, Turkey, Mexico, 
Venezuela, Romania, Saudi Arabia and Colombia (all together will present 9% CAGR in 2012-2017 and a joint market size of $82bn in 2017); 
and Countries with 2012 sales under $85/capita: Vietnam, South Africa, Algeria, Thailand, Indonesia, Egypt, Pakistan, Nigeria and Ukraine. 
(all together will present 11% CAGR in 2012-2017 and a joint market size of $45 bn in 2017) (Davidson 2012; IMS 2013). 
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Regardless of countless mergings/acquisitions, global Pharma is still an atomized industry (an 
oligopoly) since none of the top 20 drug producers (Novartis, Pfizer, Sanofi, Roche, and MSD are 
the top 5 MNEs in value (IMS 2014b))  have a share larger than 9%, despite together owing almost  
60% of global share (Mehralian and Shabaninejad 2014). Pharmaceutical firms presently spend 
one-third of total revenue on drugs marketing - twice their R&D outlay. After attaining $162 bn, 
R&D expenditure is predicted to raise at 2.4% CAGR a year in 2015-2020 (EvaluatePharma 
2014). Generics firms do not spend much in R&D  allowing drugs to be 80%-85% less costly than 
original counterparts (Tippie and Cui 2014). 
Trends 
Several trends are changing firms’ operating context, and thus urging refinements on all supply 
chain: (1) shorter product lifecycles; (2) new healthcare delivery modes; (3) stronger  regulation; 
(4) growing technology availability that may take over dispensing and supply, diminishing 
pharmacists involvement (e.g. robotics) (PME 2014); (5) parallel trade due to further industry 
atomization (efpia 2014); (6) trend toward prevention (pwc 2011); (7) growing of biosimilars 
spending (18% share in 2013 to 19-20% by 2017); (8) threat of biopharmaceuticals to displace 
traditional medications (IMS 2014a; PME 2014) (see also Figure 1 and 2) . Aiming to surpass 
economy’s quiescence and financial instability taking place in highly developed economies, a 
climbing trend for investment in pharmerging markets is a reality. 
Key Success Factors on Branded Generics 
To thrive in the market brand-generics firms have to: (1) good relationship with local governments 
and players; (2) retain local talent to scout remote areas with multi-channel engagement; (3) 
production costs; (4) continually search for the next value-added medicine, (5) detain a strong 
portfolio marketing; and (6) maximize contracting capabilities (Gilbert, Ural, and Lopez 2012). 
Michael Porter’s Forces Model 
This framework allows the analysis of the seven fundamental forces that interacting with one 
another outline industry’s profit attractiveness. It is broadly applied in industry structure analysis 
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and constitute a convenient tool for firms penetrating new markets. Forces analysis is summed up 
in Figure 1 (Appendix II for clarification).  
Despite firms recurrent cooperation, rivalry intensity of Pharma industry being still fairly high: due 
to the moderate threat of new penetrating firms (patents protection but not so high R&D expenses), 
the moderate bargaining power of customers, the somewhat moderate bargaining power of suppliers 
(atomized market), and the moderately high substitutability of pharmaceutical products (OTC and 
generics). The regulatory force influences the industry rivalry by granting some benefits to firms 
researching in priority areas. The Complements force is one that as a strong influencer of firms’ 
success, it should be explored appropriately. 
 
 
Figure 1 – Michael Porter Analysis. The Regulatory force, specific from this market, is also analysed. Each of the 
forces power change between industries and within an industry over time. API-active pharmaceutical ingredient.  
 
SWOT-TOWS Analysis 
The SWOT analysis, as a primary step towards internationalization of a firm, allows the evaluation 
of its intrinsic capabilities and external context. Then, together with a matching systematic analysis 
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(TOWS matrix), it is possible to develop a solid strategy (Figure 2). Atral should, focus on 
neutralizing its weaknesses and threats in order to achieve a sustainable competitive advantage. 
This should be done by improvement of strengths and by taking maximum advantage in market 
opportunities. The firm should continue to focus in the search of new markets and reinforcement of 
its brand equity, mainly abroad. 
 
 
Figure 2 – SWOT-TOWS analysis. CA- Central America; LA – Latin America; ME- Middle East; NHS-National 
Health System; AIM: Authorization for introduction in the market; OTC – non-prescription medicines; IRR – 
internal rate of return. 
 
Country Selection 
Why Central America 
Atral already has an internationalization attitude embedded in its genetic code; always presenting a 
market-seeking behaviour towards pursue of market share, exploitation of network advantages 
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(proactive strategy) and reinforcement of its financial status (proactive strategy). Atral has been 
aiming at markets where local industry is underdeveloped and with a pharmaceutical trade balance 
deficit, by answering to niche needs rather than parlaying in mass-market medicines.  
CA was the selected region for the study due to: (1) competitors focus in pharmerging regions 
(McKinsey 2013); (2) underpenetration by branded generics (BMI 2014); (3) regulatory 
developments towards players selection (players with lower quality standards or no proof of 
bioequivalence. are forced to exit the market due to tighter regulation) - regional regulatory 
harmonization; (4) region’s pharmaceutical trade balance deficit; (5) a 18.4% population  growth 
in 2013-2023 to 52 million (against Portuguese population’s 10.2 million in 2023); (6) a 
pharmaceutical market value of  $3.84 bn in 2014 (slightly lower than the decreasing (-17.7%) 
$4.59 bn domestic one) forecasted to grow to $4.79 bn in 2018 with a 5.5% CAGR; (7) healthcare 
expenditure of $18.3bn in 2014 (7.2% CAGR) (slightly lower than the decreasing (-17.7%) $21.53 
bn domestic one), and also an expected CAGR of 7.1% and a value of  $24.1 bn till 2018, or a 
CAGR of 7.2% and a value of $34.3 bn till 2023 (due to longer life expectancy; increased access 
to, and quality of healthcare facilities; and expansion of healthcare coverage) (BMI 2014; INE 2009; 
BMI 2015) (Appendix IV); (8) an average out-of-pocket payment of 37.3% (24.9% in Portugal) 
(2001-2013) (World Bank 2015); (9) Atral have operated in the region for 50 years till 2005 
(generics domestic penetration reduced firm resources to keep an, at the time, not profitable 
activity)13; (10) Pharbal in Peru as an opportunity to reinforce CA operations; and (10) export 
industry to these countries benefits from several international trade promoting agreements. 
Moreover there’s a fair likelihood for long-term sustainability for branded generics in CA countries 
(McKinsey 2012; Zhu and Yang 2004). Additionally, the CA penetration, are likely to benefit Atral 
with early-mover advantages on this promising region.  
However one has to be aware of some limitations of this region: the underdeveloped transportation 
infrastructure that undermines trade; the high predominance of counterfeit medicines; possible 
                                                            
13 Atral’s portfolio was obsolete and its structure was especially old, at the time. A re-structuration starts in 2006. But domestic 
hurdles leads to firm’s exit by stopping promotion. However concomitant procurement for new drugs AIMs was done.  
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market penetration by Mexican and Brazilian firms; and finally the constrained accessibility to 
third-party investment for private firms (BMI 2014). 
Scoring Model 
Despite the dominance of the seven geographies together being the utmost aim (sixth greatest 
pharmaceutical market in LA (BMI 2014)), due to resources limitation it is not viable for Atral to 
approach all CA geographies simultaneously. In accordance with this constraint a tailored scoring 
model, based on international benchmarking indicators, was used to provide Atral with few insights 
into the most alluring markets into which internationalize one of its drugs. Statistical data on several 
macro and microeconomic variables and on some firm’s particular metrics were employed and 
scored (from 0 to 5) upon normalization (Appendix V). Then weights were assigned to each 
indicator according to its relative relevance to the present study, the industry, and Atral’s strategic 
objectives. Afterwards, the performance of individual CA nations is computed by multiplying the 
weights attributed to indicators by each countries criteria’s score. In the end, nations are ranked 
again from 0 to 5 in accordance to their scores, which are used as proxies for individual country 
attractiveness (0 denotes the lowest and 5 the highest potential for internationalization). 
Criteria 
The macro indicators employed giving a general picture of each selected country socio-economic 
performance are discriminated on Table 2. Also micro indictors were used, once they allow the 
portrayal of a countries’ general business industry as a whole, and also more specifically, its 
healthcare and pharmaceutical industries, that synergistically and proportionately depend on each 
other. Firm-specific indicators were also used to assess the potential of the selected market nations, 
once these variables reflect the firm’s knowledge about the market, local brand awareness and 
easiness on penetrating each market (network of business contacts and potential local partners). The 







Table 2 – Scoring Model Macroeconomic Indicators. For more detail go to Appendix V. 
 
 





After quantitatively analyzing each country, a table ranking the selected geographical markets was 
generated in line with their attractiveness degree for Atral’s internationalization. This ranking table 
acts as a sound basis for decision-making respecting the regional market strategic goals of the firm; 
it pictures the chronological order for CA market entry that should be followed in the region for the 
top three countries, the remaining ones have to be subject to a future analysis. The most appealing 
nation for Atral’s market entry seems to be Panama (3.70/5), trailed by Costa Rica (2.98/5) and El 
Salvador (2.95/5). Belize seems to be the more risky market to address at the moment, taking into 
account the present socio-economic situation in the country and Atral’s presence there (Figure 3).  
  
Figure 3 – Ranking of CA Countries for firm internalization (1 for lowest and 5 to a highest potential). 
 
Selected Country - Panama 
Country General Portrayal 
Republic of Panama has 3.909 million people (growing at 1.6% in 2014) and is strategically located 
in the bottom of the narrow isthmus of CA. It is northerly surrounded by Caribbean Sea, southerly 
by North Pacific Ocean, easterly by Republic of Colombia, and westerly by Republic of Costa Rica 
(Appendix VI).  
Until October 2015, Panama registered a GDP of $47.473 bn, and it is forecasted to attain a GDP of 
$71.679 bn in 2020 (due to end of Panama’s Canal enlargement and several celebrations of free trade 
agreements) (IMF 2015). Following several structural reforms, and country’s takeover of Panama 
Canal in 1999, Panama turned into one of the most dynamic economies worldwide, with one of the 
fastest growth rates (GDP average growth of 8.2% in 2004-2014) and the greatest poverty and 
inequality drops, in LA. In addition, the country performed rather strongly in the global financial 
crisis, registering a 4.0% growth in 2009 while most of regional nations endured a recession. Indeed, 
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country’s economy even gained a new impetus, registering growth rates of 10.8% in 2011 and 
10.2% in 2012 (Cerdeiro and Yang 2015; FocusEconomics 2015).  
Panama trails Chile in regional rankings regarding Global Competitiveness Index, persisting as the 
most competitive economy in CA. The skill deficiency is regarded as a concern, once it endangers 
country’s progress towards more knowledge-intensive activities. Nevertheless, general 
infrastructure is commendable, with some of the world’s best port and airport facilities.  
PESTEL Analysis 
Aiming at a constructive overview of Panama, and inspection of the critical factors shaping the 
industry and affecting operating firms, a PESTEL analysis (Appendix VII) was carried out (Figure 
4). As a key constituent of strategic management it may be especially valuable for firms looking for 
new opportunities, launching commodity products/services, or approaching new markets.  
 
Figure 4 – PESTEL analysis. 
 
To analyse Panama’s culture resemblance with Portuguese one, the Hofstede’s six cultural 
dimensions model was used (Appendix VIII). They are culturally very similar (dimensions vary in 
±10 points) differing only in the distance power dimension (±32 points). Regarding this dimension 
Panama’s score mirrors a much more hierarchical society, that in an organization expresses inherent 
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inequalities (high distance between blue and white-collar); centralization is favoured, subordinates 
expect to be forwarded to their tasks, and the ideal boss is a benevolent autocrat (itim 2015).  
Pharmaceutical Industry in Panama 
Market size and Growth 
Drug sales registered $0.63 bn in 2014 ($3.84 bn in CA), from which more than 49.2% are from 
private market (BMI 2014; Hernandéz 2015); and is believed to be $0.82 bn in 2018. The average 
per capita spending is estimated to be $161.192 in 2010-2018. This raise is mainly due to a rise in 
healthcare public and private (mainly medical tourism) outlays (Appendix IX). Atral therapeutic 
classes with higher sales are Expectorants ($4.3 mn), Anxiolytics ($1.9 mn), and Cephalosporins 
($1.5mn), being its total market worth $10.9 mn (1.5 mn units)  in 2010-2014 (IMS 2015).  
Competition 
The low positive pharmaceutical trade balance deficit reflects a small local pharmaceutical industry 
(10% market share) (Hernandéz 2015). Regarding generics, in 2010, they all accounted for just 10% 
of share value against 19.1% in Portugal (Valdés 2012; Vogler and Zimmermann 2012). In 2014, 
non-branded generics accounted for 7% of sales (Hernandéz 2015) and branded ones 45% . The 
three players with highest market share are Abbott (8.1%), Pfizer (5.0%) and Sanofi (4.7%).  
Prices and Distribution 
There is a poor drug price regulation in Panama. Pharmaceutical prices are one of the main factors 
on buyers’ decision. They are set by firms (according to the social costs of the society) but if they 
want their medicines reimbursed by the government prices have to be set according to drugs 
therapeutic value relative to similar ones already authorized and/or international reference prices. 
Regarding distribution, in contrast to the portuguese market, Panama is less conservative allowing 
direct sale and distribution to retailers (no pre-/wholesaler is required).  
Trends 
Branded generics firms are attracted by drugs Panamian market due to: (1) health/drugs access 
thanks to reforms a growing purchasing power; (2) growing drug imports (already 90% in 2014), 
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and decrease of its low tariffs; (3) consolidation of public health sector (Embassy of India 2011); 
(4) raise on CPI for medical and pharmaceutical products (5.5% in 2013-2014 (Hernandéz 2015)); 
(5) trust and growing demand for branded generics; and (6) the highest Pharmaceutical Risk/Reward 
Rating (RRR) score in CA (45.2/100) (BMI 2014). Moreover, in 2010-2018, packed drugs (Atral 
style drugs) trade balance deficit is forecasted to grow negatively (i.e. imports are growing), 
generating an opportunity for foreign firms with a portfolio full of packed drugs to export (like 
Atral). However, pharmacy retail chains are starting to lead the market, which can be a problem due 
to an increase in its bargaining power. Moreover drug sales as a percentage of health outlay will 
just be 18.58% in 2010-2018, despite a health inaccessibility of 10% (World Bank 2015). 
Entry Mode  
Theoretical Background 
The way a company approaches and penetrates a market has a tremendous impact on the success of 
its operations. In this sense, Atral shall make a thoughtful strategic decision regarding the entry 
mode to employ (mode for organizing its foreign business activities) considering some trade-offs: 
risks/returns and strategic flexibility/resources commitment. The correct entry mode should grant 
the alignment of firm’s internal capabilities with goals and external context; and should be a 
strategic decision directed to the long-term (Hill, Hwang, and Kim 1990; Franklin 1994).  
Roughly, market entry modes may be classified in: export, contractual, and investment entry modes. 
Export entry modes comprise direct export activities, in which the firm handles export and shall be 
in charge of building the entire operation (sales subsidiary operation, or distributors do promotion); 
and indirect export operations, in which the firm only handles production, and another one is in 
charge of driving the marketing and sales. Contractual entry modes comprise long-term non-equity 
deals with a local firm, generally involving transfer of intangible assets (licensing, franchising, 
turnkey contracts, management contracts) (Keillor 2011; Hill, Hwang, and Kim 1990). At last, 
investment entry modes (foreign direct investment) comprises an equity investment, and may take 
two forms: wholly owned subsidiary (the firm either purchases an incumbent - merger or acquisition 
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- or invests in a new operation via greenfield venture); and joint-ventures (firm enters along with 
another firm, both sharing risks and revenues) (Keillor 2011).  
Each entry mode dictates the level of control over business activities, dissemination risk and 
resource commitment (Hill, Hwang, and Kim 1990), but also the fixed/variable costs, ROI, firm 
responsibility and market engagement.  
Entry Mode Selection 
The indirect export with outsourcing of distribution operations seems to be the most suitable entry 
mode, once Atral is able to hold a fair control over its operations, minimize dissemination risks and 
resources commitment (higher strategic flexibility), and to be fairly involved with the market to 
promote its own brand (in line with Atral’s goals) (see Table 4). Market knowledge it holds in 
Panama will help strengthen success by this entry mode. A greenfield investment would be a 
plausible future step (mainly due to Panama’s strategic location and Atral export to other LA 
countries), but having in mind the cost reduction focus of Atral, its financial status, and debilities 
the current time is not the right time for such an investment, a future analysis will be mandatory 
further in time when the time is right. 
 
Table 4 – Scoring Model for entry mode choice, based on Atral goals. Most appropriate strategies are 
highlighted in green decreasing towards red. Each goal was scored and multiplied by its relevance/weight (%). 
 
Thus, taking also in consideration firm-specific factors, Panamian drug industry traits, Pharma-
specific internationalization factors, and also country context, two different steps, not mutually 
exclusive (in time), are suggested on Atral’s internationalization. 
(1) A former one, foreseen to start during 2016, involves the selection of a distributor partner 
(maximum 6 months), concomitant with the approach of direct customers (mainly governments, 
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insurance companies; and pharmacies, to some extent), and also complements (physicians, mainly 
the opinion driver ones) to prepare them to once the contract with distributor is celebrated the 
demand from pharmacies is significant. This demand will be higher the higher the drug is 
prescribed, which in turn depends on the amount reimbursed by government or insurance firms.  
As distribution starts (2) promotion should increase specially among doctors and pharmacies. 
Regarding the government Atral should involve itself and support government health initiatives in 
order to strengthen this relationship, and its image among end-consumers. Promotion should be 
especially strong in the first five years. Regarding the enhancement of firm’s position in the 
network, the head of international department, with a fair knowledge of LA market should travel 
one time per month from headquarters to Panama City (1200€ - trip fares, business development 
expenses, accommodation and living outlays) to promote new partnerships and sales opportunities 
and provide guidance. Pharbal’s employees (700€/trip) should also be sent in the promotion field 
to enlarge customers’ base, raise brand equity; all in the second phase. However, Atral should also 
recruit a small team of three people from Panama to travel into the more remote areas, approaching 
pharmacies and doctors. A fair bonus remuneration scheme based on results should be employed to 
this team (costs €3000/month). Atral should also focus its efforts not only in the capital’s province 
(Panama) - that holds around 50% of total country’s population and the highest prices for a basic 
basket of drugs - but also in minor areas in order to conquer all population trust - future is there and 
trust has to be earn from the beginning (growth on population is being mainly driven by indigenous 
population). Exit costs are forecasted to be minimal once no equity investment is done; reputation 
costs may also be minimal if handled appropriately.  
Export Risk Assessment 
For the design of a strong implementation strategy, Atral has to have in mind Panama’s strengths 
and opportunities (its strong economic growth; political and economic stability; fairly diversified 
economy; low unemployment; character as a hub of many networks, a “place to go”, a valuable 
regional financial center, and a services hub (economy more resilient)). Country weaknesses and 
threats have also to be taken into account, such as market (future market size, growth rate and 
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health) and financial risks (availability and cost of capital) due to country-specific risks: 
susceptibility of growth, trade, and financial markets to external forces, due to country’s globally 
integrated economy; postponed reforms on financial transparency can limit country’s accessibility 
to global capital and to the international payments system; qualified labour scarcity (two-thirds of 
the labor force without an upper secondary education); poor budgetary discipline; and legal system 
ineffectiveness). The other risks are: another financial risk, i.e. capital required from outside sources 
(depending on the declining Portuguese market and unstable markets like Syria or Lybia); currency 
risk (monetary unit is the Panamanian Balboa, traded at par value with the US$.); management risk 
(experience of Panama’s hired team and its dynamics); Business risk (tighter regulations may 
develop in pharmaceuticals market; and margins may get narrower due to increased government 
role in drugs pricing and future increase in non-branded generics) technology risk (product 
substitution, since as a branded generic, the raise on non-branded may steel customers and 
complements) and competitive risk (future level of non-branded generics) (Appendix X). 
Conclusions  
The threat by big MNEs has driven Atral to concentrate its efforts on niche segments to minimize 
competition, and parlay on the diversification of business opportunities, to strengthen its brand 
position. However, domestic market hurdles have turned a proactive internationalization strategy 
into a more reactive one. In this work, the country selected for Atral’s penetration was Panama. It 
presents an exemplar economic performance over the last and future years, as the best among CA 
countries and one of the best in LA; the highest human development index. Moreover it has the best 
Pharmaceutical RRR and the best suitability for doing business, among CA countries; and the title 
of world’s happiest country for the last two years. Moreover countless healthcare reforms are being 
made, that together with economic growth will drive up pharmaceuticals access and consumption. 
It is also the country in which Atral still holds most of its CA’s AIMs, meaning that it is not only 
easier to leverage its network, but also after conquering customers trust again a lot more products 
will be easily introduced in the market. Panama is just the first step of a whole new journey, in 
which by focusing in its solid introduction there the re-launching of the brand in the whole CA will 
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have a whole new impetus. The model of resource adjustment is thought to explain firm’s current 
internationalization, stating that Atral is reliant on the evolution potential of crucial internal and 
external resources that can be adjusted within the firm and between it and business context; 
recognizing Atral’s network of relations importance. In this sense Atral’s internationalization 
process will start the moment the firm starts approaching customers and complements from 
Panama’s industry network, in a two stage process characterized by a distribution outsourcing.  
The product that seems to be the most appropriate to start commercializing is BetamoxPlus in tablets 
and oral suspension (forecasted annual revenues of €1.5 mn for 500.000 units sold) once 312,137 
people go to outpatient care with problems treated by BetamoxPlus (Ministerio de la Salud Panama 
2014) - one of Atral’s key products in Portugal (10% of sales in a 60 products portfolio). Moreover 
there is a globalized trend towards leaving antibiotics business to focus on chronic diseases. 
Limitations and Further Research 
The scoring model outcome is a valuable tool that acts as a sound basis for decision-making 
respecting a regional market penetration. However, a comprehensive appraisal on all selected 
markets regarding customer structure and competitive context (listing opportunities and 
challenges), should have been appropriate. Thus, although Costa Rica’s macro situation being not 
that attractive as Panama’s, several Pharma-related indicators suggest market specific potential: the 
highest position in Ease of Doing Business Rank, close position to Panama in the Pharmaceutical 
RRR (42 for Costa Rica versus 45.2 for Panama), and highest Health Expenditure per Capita, Public 
Health Outlay, Health Expenditure Average Growth, Pharmaceutical Industry Turnover and sales 
growth comparing to Panama (Appendix V). Moreover it has the 36th best NHS compared to US 
(the only CA country in this ranking)(Business Insider 2012). In this sense Costa Rica deserves a 
more thorough analysis despite the significant difference in values. A financial analysis on 
internationalization to Panama should be performed as a future analysis step to guarantee success. 
The analysis was constrained by the lack of information regarding branded generics for the targeted 
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